Skip to main content

Table 4 Associated renoprotective effects of SGLT2 inhibitors, results from randomized controlled trials

From: The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

Study

Drugs

Composite outcomea

Progression of albuminuria

dSCr

Renal death

ESKD

40% eGFR reduction

CANVAS Programb [78, 85]

Canagliflozin

5.5

89.4

1.2

 

0.4

5.3

Placebo

9.0

128.7

2.4

 

0.6

8.7

P value

0.3868

0.0184

    

CREDENCE [70]

Canagliflozin

11.1

 

5.4

0.1

5.3

3.5

Placebo

15.5

 

8.5

0.2

7.5

5.7

P value

0.00001

 

< 0.001

 

0.002

 

DECLARE–TIMI 58 [93]

Dapagliflozin

1.5

  

0.1

0.1

1.4

Placebo

2.6

  

0.1

0.2

2.5

P value

< 0.0001

  

0.32

0.013

< 0.0001

DAPA-CKD [122]

Dapagliflozin

6.6

  

< 0.1

5.1

5.2

Placebo

11.3

  

0.3

7.5

9.3

P value

< 0.001

     

EMPEROR-Reduced [68]

Empagliflozin

1.6

     

Placebo

3.1

     

P value

     

< 0.001

EMPA-REG OUTCOME [86]

Empagliflozin

1.7

11.2

1.5

   

Placebo

3.1

16.2

2.6

   

P value

< 0.001

< 0.001

< 0.001

   

VERTIS CV [11]

Ertugliflozin

3.2

 

3.1

0

  

Placebo

3.9

 

3.8

0

  
  1. dSCr doubling of serum creatinine, ESKD end-stage kidney disease, eGFR estimated glomerular filtration rate
  2. aPrimary renal composite outcome
  3. bRate 1000 people per year
  4. cP value for homogeneity between CANVAS and CANVAS-R